Abstract
Recent advances in molecular diagnostics classify Langerhans cell histiocytosis as an orphan disease strongly dependent on alterations in MAP kinase pathway, most prominently BRAF V600E mutation. Molecular targeted therapy with vemurafenib often leads to long-term remission. Efforts to expand therapeutic approaches include MEK inhibition or modulation of cellular senescence.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
